Rowland Charles A Jr — SEC Form 4 filings
SEC reporting owner CIK 1383292. 7 Form 4 filings on record with FilingPulse; latest filed 2026-02-09.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-01-24 to 2026-02-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 60,000 shares, $2,134,278 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 22.
- Largest priced transaction: sale of 60,000 shares @ $35.57 ($2,134,278) in Viking Therapeutics, Inc., filed 2025-10-28.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | Director | 3 | — | 1 leg · 60,000 sh · $2,134,278 | 9 |
| Generation Bio Co. (GBIO) | Director | 3 | — | — | 10 |
| Orchard Therapeutics plc (ORTX) | Director | 1 | — | — | 3 |
Form 4 filings — Rowland Charles A Jr
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-09 | 4 | Generation Bio Co. (GBIO) | Code (U): 53,475 · Disposition to issuer (D): 3,000 (derivative) · Disposition to issuer (D): 4,246 (derivative) · Disposition to issuer (D): 5,200 (derivative) · Disposition to issuer (D): 1,500 (derivative) · Disposition to issuer (D): 1,920 (derivative) · +2 more | EDGAR |
| 2026-01-05 | 4 | Viking Therapeutics, Inc. (VKTX) | Grant/award (A): 3,150 @ $0 · Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2025-10-28 | 4 | Viking Therapeutics, Inc. (VKTX) | Grant/award (A): 16,000 @ $4.48 · Grant/award (A): 22,000 @ $5.80 · Grant/award (A): 22,000 @ $4.88 · Sale (S): 60,000 @ $35.57 · Option exercise (M): 16,000 (derivative) @ $0 · Option exercise (M): 22,000 (derivative) @ $0 · +1 more | EDGAR |
| 2025-06-06 | 4 | Generation Bio Co. (GBIO) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Viking Therapeutics, Inc. (VKTX) | Grant/award (A): 18,800 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Generation Bio Co. (GBIO) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-01-24 | 4 | Orchard Therapeutics plc (ORTX) | Disposition to issuer (D): 12,294 · Disposition to issuer (D): 46,000 (derivative) @ $0 · Disposition to issuer (D): 105,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1383292 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →